<unk>  is an antineopalstic agent that is FDA approved for the treatment of reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer.   Common adverse reactions include alopecia, Nausea, Vomiting, fatigue/Malaise, anorexia, stomatitis, fever, infection, diarrhea, Pain at injection site, sepsis, neurotoxicity, hemorrhage, extravasation, streaking/Erythema, phlebitis, esophagitis, dysphagia..
Dexrazoxane
Guanoxan
Metenolone
Mitotane
Idebenone
Fluocortolone
Bromadiolone
Oxymetholone